Imagine fighting a battle where your weapons stop working because the enemy changes its armor. This is exactly what happens with some cancers driven by the FGFR2 gene. Researchers looked at thirty patients in the ReFocus trial and the UNLOCK program at Gustave Roussy. They wanted to see if a new drug called lirafugratinib could work and what happened when the cancer started to resist it.
The team found that in most cases, the cancer developed specific mutations in the FGFR2 gene after the drug stopped working. These changes were different from those seen with an older drug called futibatinib. Interestingly, the specific mutations that usually stop futibatinib from working were very rare in this group. This suggests the two drugs might attack the cancer in slightly different ways.
Three patients who stopped responding to lirafugratinib switched to futibatinib. All three saw their disease stay under control for a long time. This is promising, but the study has limits. With only thirty patients, the results are a starting point, not a final answer. The researchers used lab models to support their findings, but these small early steps do not yet prove that switching drugs is safe or effective for everyone.
